Chemex announces completion of merger with ACCESS Pharmaceuticals.TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jan. 29, 1996--Chemex Pharmaceuticals Inc., today announced that at a Special Shareholders Meeting held on January 25, 1996, its shareholders approved the merger with ACCESS Pharmaceuticals of Dallas. The merger has been subsequently closed. ACCESS has been merged into Chemex which is the surviving legal entity. Pursuant to the terms of the Merger Agreement all of the outstanding shares of ACCESS were exchanged for 13,920,000 shares of common stock of Chemex, the issuance of which was registered with the SEC by way of a registration statement. The Chemex name has been changed to ACCESS Pharmaceuticals Inc. and the principal office moved to 2600 N. Stemmons Freeway, Dallas, Texas “Dallas” redirects here. For other uses, see Dallas (disambiguation). The City of Dallas (pronounced [ˈdæl.əs] or [ˈdæl. 75207. Chemex share certificates will not be exchanged. ACCESS share certificates will be exchanged in due course. Chemex, now ACCESS Pharmaceuticals Inc. will continue to be traded on NASDAQ's Bulletin Board and the symbol will remain CHMX until a new symbol is approved. Kerry Gray will be president and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of ACCESS. In addition to Gray the Board of Directors will be: Herbert McDade Jr., chairman Elizabeth Greetham Michael Flinn Dr. David Ranney, the founder of ACCESS ACCESS Pharmaceuticals is an emerging pharmaceutical company with a broad platform technology for enhancing the site targeting of intravenous therapeutic drugs, MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. contrast agents and radiopharmaceutical radiopharmaceutical /ra·dio·phar·ma·ceu·ti·cal/ (-fahr?mah-soo´ti-k'l) a radioactive pharmaceutical, nuclide, or other chemical used for diagnostic or therapeutic purposes. diagnostic and therapeutic agents. The ACCESS technology is based on natural carbohydrate carbohydrate, any member of a large class of chemical compounds that includes sugars, starches, cellulose, and related compounds. These compounds are produced naturally by green plants from carbon dioxide and water (see photosynthesis). carriers. The technology development of ACCESS is currently focused on increasing the therapeutic benefit of oncology oncology /on·col·o·gy/ (ong-kol´ah-je) the sum of knowledge regarding tumors; the study of tumors. on·col·o·gy n. agents and improving the efficiency of oncology diagnosis by selectively targeting sites of disease and accelerating drug clearance. CONTACT: Kerry P. Gray, 214/905-5100 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion